Literature DB >> 26598551

Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition.

Miju Kim1, Minchul Kim1, Seong-Jun Park2, Cheolju Lee3, Dae-Sik Lim4.   

Abstract

LATS1/2 (large tumor suppressor) kinases and the Angiomotin family proteins are potent inhibitors of the YAP (yes-associated protein) oncoprotein, but the underlying molecular mechanism is not fully understood. Here, we report for the first time that USP9X is a deubiquitinase of Angiomotin-like 2 (AMOTL2) and that AMOTL2 mono-ubiquitination is required for YAP inhibition. USP9X knockdown increased the LATS-mediated phosphorylation of YAP and decreased the transcriptional output of YAP. Conversely, over-expression of USP9X reactivated YAP in densely cultured cells. Both genetic and biochemical approaches identified AMOTL2 as a target of USP9X. AMOTL2 was found to be ubiquitinated at K347 and K408, which both reside in the protein's coiled-coil domain. The AMOTL2 K347/408R mutant, which cannot be ubiquitinated, was impaired in its ability to inhibit YAP. Furthermore, ubiquitinated AMOTL2 can bind to the UBA domain of LATS kinase, and this domain is required for the function of LATS. Our results provide novel insights into the activation mechanisms of core Hippo pathway components.
© 2015 The Authors.

Entities:  

Keywords:  AMOTL2; Hippo pathway; LATS‐YAP; USP9X; mono‐ubiquitination

Mesh:

Substances:

Year:  2015        PMID: 26598551      PMCID: PMC4718409          DOI: 10.15252/embr.201540809

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  47 in total

1.  Angiomotin-like proteins associate with and negatively regulate YAP1.

Authors:  Wenqi Wang; Jun Huang; Junjie Chen
Journal:  J Biol Chem       Date:  2010-12-27       Impact factor: 5.157

2.  The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis.

Authors:  Chunling Yi; Zhewei Shen; Anat Stemmer-Rachamimov; Noor Dawany; Scott Troutman; Louise C Showe; Qin Liu; Akihiko Shimono; Marius Sudol; Lars Holmgren; Ben Z Stanger; Joseph L Kissil
Journal:  Sci Signal       Date:  2013-09-03       Impact factor: 8.192

3.  YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response.

Authors:  Luca Azzolin; Tito Panciera; Sandra Soligo; Elena Enzo; Silvio Bicciato; Sirio Dupont; Silvia Bresolin; Chiara Frasson; Giuseppe Basso; Vincenza Guzzardo; Ambrogio Fassina; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Cell       Date:  2014-06-26       Impact factor: 41.582

4.  Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein.

Authors:  Michael DeRan; Jiayi Yang; Che-Hung Shen; Eric C Peters; Julien Fitamant; Puiyee Chan; Mindy Hsieh; Shunying Zhu; John M Asara; Bin Zheng; Nabeel Bardeesy; Jun Liu; Xu Wu
Journal:  Cell Rep       Date:  2014-10-16       Impact factor: 9.423

5.  Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.

Authors:  Zhongyuan Wang; Yanping Wu; Haifeng Wang; Yangqing Zhang; Lin Mei; Xuexun Fang; Xudong Zhang; Fang Zhang; Hongbo Chen; Ying Liu; Yuyang Jiang; Shengnan Sun; Yi Zheng; Na Li; Laiqiang Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

6.  Elucidation of a universal size-control mechanism in Drosophila and mammals.

Authors:  Jixin Dong; Georg Feldmann; Jianbin Huang; Shian Wu; Nailing Zhang; Sarah A Comerford; Mariana F Gayyed; Robert A Anders; Anirban Maitra; Duojia Pan
Journal:  Cell       Date:  2007-09-21       Impact factor: 41.582

7.  FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination.

Authors:  Sirio Dupont; Anant Mamidi; Michelangelo Cordenonsi; Marco Montagner; Luca Zacchigna; Maddalena Adorno; Graziano Martello; Michael J Stinchfield; Sandra Soligo; Leonardo Morsut; Masafumi Inui; Stefano Moro; Nicola Modena; Francesco Argenton; Stuart J Newfeld; Stefano Piccolo
Journal:  Cell       Date:  2009-01-09       Impact factor: 41.582

8.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control.

Authors:  Bin Zhao; Xiaomu Wei; Weiquan Li; Ryan S Udan; Qian Yang; Joungmok Kim; Joe Xie; Tsuneo Ikenoue; Jindan Yu; Li Li; Pan Zheng; Keqiang Ye; Arul Chinnaiyan; Georg Halder; Zhi-Chun Lai; Kun-Liang Guan
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

9.  Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.

Authors:  Shan Wang; Rahul K Kollipara; Nishi Srivastava; Rui Li; Preethi Ravindranathan; Elizabeth Hernandez; Eva Freeman; Caroline G Humphries; Payal Kapur; Yair Lotan; Ladan Fazli; Martin E Gleave; Stephen R Plymate; Ganesh V Raj; Jer-Tsong Hsieh; Ralf Kittler
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-03       Impact factor: 11.205

10.  Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway.

Authors:  Jung-Soon Mo; Zhipeng Meng; Young Chul Kim; Hyun Woo Park; Carsten Gram Hansen; Soohyun Kim; Dae-Sik Lim; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2015-03-09       Impact factor: 28.824

View more
  29 in total

1.  Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway.

Authors:  Chu Zhu; Xinyan Ji; Haitao Zhang; Qi Zhou; Xiaolei Cao; Mei Tang; Yuan Si; Huan Yan; Li Li; Tingbo Liang; Xin-Hua Feng; Bin Zhao
Journal:  J Biol Chem       Date:  2017-11-28       Impact factor: 5.157

2.  Deubiquitinase YOD1 potentiates YAP/TAZ activities through enhancing ITCH stability.

Authors:  Youngeun Kim; Wantae Kim; Yonghee Song; Jeong-Rae Kim; Kyungjoo Cho; Hyuk Moon; Simon Weonsang Ro; Eunjeong Seo; Yeon-Mi Ryu; Seung-Jae Myung; Eek-Hoon Jho
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-17       Impact factor: 11.205

3.  Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.

Authors:  Sebastian Mana-Capelli; Dannel McCollum
Journal:  J Biol Chem       Date:  2018-09-28       Impact factor: 5.157

4.  Angiomotin-like 2 interacts with and negatively regulates AKT.

Authors:  H Han; B Yang; W Wang
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

Review 5.  The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway.

Authors:  Noa Furth; Yael Aylon
Journal:  Cell Death Differ       Date:  2017-06-23       Impact factor: 15.828

6.  The Hsp70-Bag3 complex modulates the phosphorylation and nuclear translocation of Hippo pathway protein Yap.

Authors:  Simone Baldan; Anatoli B Meriin; Julia Yaglom; Ilya Alexandrov; Xaralabos Varelas; Zhi-Xiong Jim Xiao; Michael Y Sherman
Journal:  J Cell Sci       Date:  2021-12-02       Impact factor: 5.285

7.  Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition.

Authors:  Miju Kim; Minchul Kim; Seong-Jun Park; Cheolju Lee; Dae-Sik Lim
Journal:  EMBO Rep       Date:  2015-11-23       Impact factor: 8.807

8.  Serine Metabolism Regulates YAP Activity Through USP7 in Colon Cancer.

Authors:  Xiaoya Zhao; Jianfei Fu; Bin Hu; Lin Chen; Jing Wang; Jinyong Fang; Chenyang Ge; Haiping Lin; Kailing Pan; Liang Fu; Lude Wang; Jinlin Du; Wenxia Xu
Journal:  Front Cell Dev Biol       Date:  2021-05-12

9.  Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.

Authors:  Aleksandra Toloczko; Fusheng Guo; Hiu-Fung Yuen; Qing Wen; Stephen A Wood; Yan Shan Ong; Pei Yi Chan; Asfa Alli Shaik; Jayantha Gunaratne; Mark J Dunne; Wanjin Hong; Siew Wee Chan
Journal:  Cancer Res       Date:  2017-07-18       Impact factor: 12.701

10.  SUMOylation activates large tumour suppressor 1 to maintain the tissue homeostasis during Hippo signalling.

Authors:  Liu Mei; Meiyu Qv; Hangyang Bao; Qiangqiang He; Yana Xu; Qin Zhang; Wei Shi; Qianlei Ren; Ziyi Yan; Chengyun Xu; Chao Tang; Musaddique Hussain; Ling-Hui Zeng; Ximei Wu
Journal:  Oncogene       Date:  2021-07-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.